Pre-specified indirect analyses of SURPASS-CVOT and REWIND, supported by sensitivity analyses, suggest that tirzepatide may reduce MACE-3 versus placebo in type 2 diabetes mellitus with CVD.
This presentation summarizes the key findings based on pulmonologists’ perspectives from a survey conducted to understand clinicians perspectives and practice patterns in both the diagnosis and treatment of group 1 and group 3 PH, which can further help optimize the management of PH patients.